An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014

An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014–2017

Published:2020-11 Issue: Volume:46 Page:102521
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Vermersch Patrick,Suchet Laurent,Colamarino Renato,Laurendeau Caroline,Detournay Bruno^ORCID

Funder

SANOFI France

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,General Medicine

Reference21 articles.

1. American Academy of Neurology. Practice guideline: disease-modifying therapies for adults with multiple sclerosis. April 2018.

2. Intention to treat analysis, compliance, drop-outs and how to deal with missing data in clinical research: a review;Armijo-Olivo;Phys. Ther. Rev.,2009

3. First line therapy in relapsing remitting multiple sclerosis;Biotti;Revue de neurologie,2018

4. Switching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: data from a retrospective cohort study;Buard;Mult. Scler. Relat. Disord.,2019

5. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation;Charlson;J. Chron. Dis.,1987

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The patient-reported outcomes for the new brand-generic teriflunomide in relapsing-remitting multiple sclerosis;Clinical Neurology and Neurosurgery;2024-11

2. Real‐world persistence of multiple sclerosis disease‐modifying therapies;European Journal of Neurology;2024-04-03

3. REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program;Neurology and Therapy;2024-03-26

4. TAURUS-MS II: real-world use of teriflunomide in Germany and changes in treatment patterns over time;Therapeutic Advances in Neurological Disorders;2024-01

5. Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study;Neurology Perspectives;2023-10